Skip directly to content

Safety Information

XALATAN®(latanoprost ophthalmic solution)

Indications and Clinical Use:

XALATAN is indicated for the reduction of
intraocular pressure in patients with open-angle glaucoma or ocular hypertension. XALATAN may be used for the reduction of intraocular pressure in patients with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty.

Contraindications:

  • Known hypersensitivity to benzalkonium chloride or any other ingredient in XALATAN.

Relevant warnings and precautions:

  • Changes to pigmented tissues
  • Macular edema, including cystoid macular edema
  • Bacterial keratitis
  • Use of contact lenses (remove 15 mins prior to administration, then reinsert 15 mins after)
  • Use in pregnancy
  • Use in nursing mothers
  • Use in pediatrics
  • Use in patients with a history of/active intraocular inflammation or herpetic keratitis
  • Use in patients with severe or uncontrolled asthma
  • Use in patients with renal or hepatic impairment

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information.

XALATAN ® Pfizer Health AB, owner/Pfizer Canada Inc., Licensee

XALACOM®(latanoprost and timolol)

Indications and Clinical Use:

XALACOM is indicated for the reduction of
intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are
insufficiently responsive to beta-adrenergic blocking agents, prostaglandins, or other IOP lowering agents AND when the use of XALACOM is considered appropriate. XALACOM should not be used to initiate therapy.

Contraindications:

  • Reactive airway disease including history of/active bronchial asthma, or severe chronic obstructive pulmonary disease
  • Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, or cardiogenic shock
  • Known hypersensitivity to any component of XALACOM

Serious warnings and precautions:

Cardiac reactions: Death associated with cardiac failure has been reported. Cardiac failure should be adequately controlled before beginning treatment. At the first sign of cardiac failure, XALACOM should be discontinued.

Respiratory reactions: Severe respiratory reactions including death due to bronchospasm in patients with asthma have been reported following administration of beta-adrenergic blocking agents.

Anaphylactic reactions: While taking beta-adrenergic blocking agents, patients with a history of atopy or severe anaphylactic reaction to a variety of allergens may be more sensitive to repeated challenge.

Other relevant warnings and precautions:

  • Systemic effects
  • Additional effects of beta-adrenergic blockade
  • Thyrotoxicosis
  • Muscle weakness
  • Ocular effects and changes to pigmented tissues
  • Concomitant therapy: Oral or local beta adrenergic blocking agents; other prostaglandin analogues or prostaglandin derivatives; oral calcium channel blockers; catecholamine-depleting drugs; antiarrythmics; digitalis glycosides; parasympathomimetics; narcotics; guanethidine; monoamine oxidase inhibitors; CYP2D6 inhibitors; epinephrine; antidiabetic agents; eyedrops containing thimerosal.
  • Peri-operative considerations (anesthesia)
  • Should not be used in the treatment of acute closed-angle glaucoma
  • Use of contact lenses
  • Use in pregnancy
  • Use in nursing mothers
  • Use in pediatrics
  • Use in patients with renal or hepatic impairment
  • Use in patients with a history of/active herpetic keratitis
  • Use in patients with certain vascular disorders
  • Use in patients with respiratory disorders
  • Ability to drive and use of machines

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information.

XALACOM ® Pfizer Enterprises SARL, owner/Pfizer Canada Inc., Licensee